Diana Kennedy
Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1053429159
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 499 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,222 and has fallen 87.4% since, to $281 in 2023.
Across 499 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$939
- Novo Nordisk$875
- AstraZeneca$813
- Abbott$658
- Boehringer Ingelheim$609
- Lilly USA, LLC$547
- plus $4K from 29 others
What the payments were for
- Food & beverage$8,292100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 60 | $939 |
| Novo Nordisk | 53 | $875 |
| AstraZeneca | 42 | $813 |
| Abbott | 30 | $658 |
| Boehringer Ingelheim | 40 | $609 |
| Lilly USA, LLC | 34 | $547 |
| Tandem Diabetes Care, Inc. | 21 | $382 |
| Corcept Therapeutics | 19 | $370 |
| Mannkind Corporation | 23 | $348 |
| Amarin Pharma, Inc. | 21 | $341 |
| Bayer | 22 | $325 |
| AbbVie(2 entities) | 19 | $321 |
| Xeris Pharmaceuticals, Inc. | 20 | $299 |
| Dexcom, Inc. | 15 | $251 |
| Insulet Corporation | 14 | $201 |
| Kowa Pharmaceuticals America, Inc. | 12 | $196 |
| Sanofi-aventis U.S. LLC | 9 | $143 |
| Radius Health, Inc. | 7 | $116 |
| Medtronic(2 entities) | 5 | $78 |
| Shire North American Group Inc | 4 | $72 |
| Johnson & Johnson | 3 | $45 |
| Endo Pharmaceuticals Inc. | 3 | $42 |
| IBSA Pharma Inc. | 3 | $42 |
| Novartis | 3 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Merck | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Antares Pharma, Inc. | 1 | $18 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $12 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
| Aegerion Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre 2$133
- Vascepa$125
- FARXIGA$119
How this compares
$8,292 in reported general payments places this provider in the 75th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Oklahoma City
- Christian MangrumOklahoma City$54K
- Robert ScofieldOklahoma City$15K
- Donny WynnOklahoma City$11K
- Cheryl BlackOklahoma City$8K
- Ali TipuOklahoma City$8K
- Amanda LagrecaOklahoma City$7K
- Bassam ArodakOklahoma City$6K
- Myrto EliadesOklahoma City$5K
- Hamsa AljumailiOklahoma City$5K
- Modhi GudeOklahoma City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.